EVOTEC SE (EVT.DE) Stock Price & Overview
FRA:EVT • DE0005664809
The current stock price of EVT.DE is 5.652 EUR. Today EVT.DE is up by 6.56%. In the past month the price decreased by -10.94%. In the past year, price decreased by -14.3%.
EVT.DE Key Statistics
- Market Cap
- 2.007B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.11
- Dividend Yield
- N/A
EVT.DE Stock Performance
EVT.DE Stock Chart
EVT.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EVT.DE. When comparing the yearly performance of all stocks, EVT.DE is a bad performer in the overall market: 80.48% of all stocks are doing better.
EVT.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVT.DE. While EVT.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
EVT.DE Earnings
On November 5, 2025 EVT.DE reported an EPS of -0.12 and a revenue of 163.89M. The company missed EPS expectations (-3.31% surprise) and missed revenue expectations (-9.17% surprise).
EVT.DE Forecast & Estimates
13 analysts have analysed EVT.DE and the average price target is 9.07 EUR. This implies a price increase of 60.42% is expected in the next year compared to the current price of 5.652.
For the next year, analysts expect an EPS growth of 50.73% and a revenue growth -2.87% for EVT.DE
EVT.DE Groups
Sector & Classification
EVT.DE Financial Highlights
Over the last trailing twelve months EVT.DE reported a non-GAAP Earnings per Share(EPS) of -1.11. The EPS decreased by -136.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| Debt/Equity | 0.48 |
EVT.DE Ownership
EVT.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 56S1 | SARTORIUS STEDIM BIOTECH | 32.72 | 17.485B | ||
| SRT3 | SARTORIUS AG-VORZUG | 38.33 | 16.818B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 32.75 | 16.259B | ||
| SRT | SARTORIUS AG | 30.71 | 13.344B | ||
| QIA | QIAGEN N.V. | 17.61 | 8.384B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.6 | 2.118B | ||
| GXI | GERRESHEIMER AG | 5.72 | 556.439M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 15.6 | 248.175M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 159M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About EVT.DE
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,788 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
EVOTEC SE
Essener Bogen 7
Hamburg HAMBURG DE
Employees: 4740
Phone: 4940560810
EVOTEC SE / EVT.DE FAQ
Can you describe the business of EVOTEC SE?
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,788 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
What is the current price of EVT stock?
The current stock price of EVT.DE is 5.652 EUR. The price increased by 6.56% in the last trading session.
Does EVOTEC SE pay dividends?
EVT.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVT stock?
EVT.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in EVOTEC SE be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EVT.DE.
Can you provide the growth outlook for EVOTEC SE?
The Revenue of EVOTEC SE (EVT.DE) is expected to decline by -2.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of EVT stock?
EVOTEC SE (EVT.DE) has a market capitalization of 2.01B EUR. This makes EVT.DE a Mid Cap stock.